Replimune Group Inc. will resubmit its experimental melanoma drug RP1 to the U.S. Food and Drug Administration for a third review [1].
The move signals a critical turning point for the biotech company, which is attempting to secure a market for its cancer immunotherapy after facing significant regulatory hurdles.
The company announced the plan on Friday, and said it has reached an agreement with the FDA on a path forward [1, 2]. This follows two prior rejections of the drug by the agency [3].
Market reaction to the news was immediate. Shares of Replimune rose 86% to $8 following the announcement [2].
The resubmission comes during a period of transition for the regulator. Reports indicate the move follows a shakeup in FDA leadership [3]. Replimune had previously criticized the agency for providing inconsistent guidance during the earlier review processes [1, 2].
RP1 is designed to treat melanoma, a form of skin cancer. The company's ability to navigate the FDA's requirements on this third attempt will determine if the immunotherapy reaches patients in the U.S. market.
While the company has not detailed the specific changes to its application, the agreement with the FDA suggests an alignment on the data, or clinical endpoints, required for approval [1]. The company continues to pursue the drug's viability despite the previous setbacks [3].
“Shares of Replimune rose 86% to $8 following the announcement”
The resubmission of RP1 highlights the volatility of biotech valuations based on regulatory milestones. By aligning with a transitioning FDA leadership, Replimune is attempting to resolve a deadlock caused by inconsistent guidance. If successful, it demonstrates that persistent clinical resubmissions can overcome initial regulatory failure, provided there is a clear agreement on the path to approval.
